Literature DB >> 21958875

Vascular contribution of adrenomedullin to microcirculatory improvement in experimental colitis.

Elena Talero1, Maria Alvarez de Sotomayor, Susana Sánchez-Fidalgo, Virginia Motilva.   

Abstract

The effect of adrenomedullin (AM), a peptide that has demonstrated vasodilatory activity, was studied in the colon and small mesenteric arteries of rats in a chronic model of inflammatory bowel disease. AM (50 ng/kg/day) was administered i.p. daily, starting 24h after trinitrobenzensulfonic acid (TNBS, 30 mg) instillation. After 14 days, rats were sacrificed, colons were macroscopically analyzed and biochemical parameters (myeloperoxidase activity, cytokines, cyclooxygenase-2 (COX-2) as well as inducible nitric oxide synthase (iNOS) expression) were determined. Vascular function of small mesenteric arteries was assessed by addition of phenylephrine (10⁻⁸ to 10⁻⁴ mol/L) and participation of COX and NOS pathways was also evaluated by using different inhibitors: indomethacin, NS-398, L-NNA, and 1400 w. Chronic AM treatment significantly reduced colonic macroscopic damage and inflammation markers. TNBS instillation induced COX-2 and iNOS expressions in colon and small mesenteric arteries; AM treatment decreased COX-2 expression only in microvessels from rats with colitis. An attenuation of phenylephrine-induced contraction was detected in small mesenteric arteries from both TNBS and AM-treated rats. COX and NOS inhibitors altered the contractile ability of phenylephrine in small mesenteric arteries from TNBS rats, suggesting the involvement of COX-2 and iNOS derived factors in the deleterious effect of TNBS on vascular reactivity; AM administration was able to reduce such alteration. Finally, treatment with the peptide significantly reduced colonic nitric oxide (NO) levels, without affecting plasma concentration. In conclusion, AM showed beneficial effects in the restoration of vascular function through the regulation of vasoactive products derived from COX-2 and iNOS. Copyright Â
© 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21958875     DOI: 10.1016/j.ejphar.2011.09.032

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  Adrenomedullin Therapy in Patients with Refractory Ulcerative Colitis: A Case Series.

Authors:  Shinya Ashizuka; Haruhiko Inatsu; Toshihiro Kita; Kazuo Kitamura
Journal:  Dig Dis Sci       Date:  2015-10-15       Impact factor: 3.199

2.  Lack of Adrenomedullin Aggravates Acute TNBS-Induced Colitis Symptoms in Mice, Especially in Females.

Authors:  Sonia Martínez-Herrero; Ignacio M Larrayoz; Judit Narro-Íñiguez; Susana Rubio-Mediavilla; Alfredo Martínez
Journal:  Front Physiol       Date:  2017-12-19       Impact factor: 4.566

3.  Adrenomedullin: A Novel Therapy for Intractable Crohn's Disease with a Loss of Response to Infliximab.

Authors:  Shinya Ashizuka; Nobuko Kuroishi; Koji Nakashima; Haruhiko Inatsu; Toshihiro Kita; Kazuo Kitamura
Journal:  Intern Med       Date:  2019-02-01       Impact factor: 1.271

4.  Safety, Tolerability, and Pharmacokinetics of Adrenomedullin in Healthy Males: A Randomized, Double-Blind, Phase 1 Clinical Trial.

Authors:  Toshihiro Kita; Yoshikazu Kaji; Kazuo Kitamura
Journal:  Drug Des Devel Ther       Date:  2020-01-06       Impact factor: 4.162

Review 5.  Antioxidant therapy for treatment of inflammatory bowel disease: Does it work?

Authors:  Fabiana Andréa Moura; Kívia Queiroz de Andrade; Juliana Célia Farias Dos Santos; Orlando Roberto Pimentel Araújo; Marília Oliveira Fonseca Goulart
Journal:  Redox Biol       Date:  2015-10-23       Impact factor: 11.799

6.  Fucoxanthin-Containing Cream Prevents Epidermal Hyperplasia and UVB-Induced Skin Erythema in Mice.

Authors:  Azahara Rodríguez-Luna; Javier Ávila-Román; María Luisa González-Rodríguez; María José Cózar; Antonio M Rabasco; Virginia Motilva; Elena Talero
Journal:  Mar Drugs       Date:  2018-10-10       Impact factor: 5.118

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.